You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物(01801.HK):一季度達伯舒®(信迪利單抗注射液)銷售收入超7億元
格隆匯 04-27 18:48

格隆匯 4 月 27日丨信達生物(01801.HK)發佈公吿,達伯舒®(信迪利單抗注射液)是由集團與禮來製藥共同開發、並於2019年3月成功推出。2021年第一季度,達伯舒®(信迪利單抗注射液)有關銷售收入超過人民幣7億元。

2021年,公司繼續發揮達伯舒®(信迪利單抗注射液)作為首款進入國家醫保目錄的PD-1抑制劑的先發優勢,進一步拓寬和加深城市及醫院覆蓋、積極採取有競爭力的綜合性市場策略以及匹配擴張銷售推廣團隊。2021年第一季度,達伯舒®(信迪利單抗注射液)持續取得令人鼓舞的銷售表現,產品銷售量持續保持逐季增長態勢。公司相信這表明達伯舒®(信迪利單抗注射液)在中國的強大市場潛力以及公司作為高品質廠商的商業化能力。

此外,達伯舒®(信迪利單抗注射液)於2021年2月獲批用於治療一線非鱗狀非小細胞肺癌,是達伯舒®(信迪利單抗注射液)獲批的第二項適應症。達伯舒®(信迪利單抗注射液)另有三項適應症的補充新藥申請(sNDA)在審評審批中,包括一線鱗狀非小細胞肺癌、一線肝細胞癌和二線鱗狀非小細胞肺癌,預計將於2021至2022年初陸續獲批。公司相信更多適應症的潛在獲批將使得達伯舒®(信迪利單抗注射液)在2021年惠及到更多癌症患者羣體。公司將繼續致力開發、製造並商業化老百姓用得起的高品質生物藥。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account